Glaukos Corp (GKOS): Thomas William Burns , Chief Executive Officer of Glaukos Corp sold 162,254 shares on Jul 12, 2016. The Insider selling transaction was reported by the company on Jul 13, 2016 to the Securities and Exchange Commission. The shares were sold at $30.03 per share for a total value of $4,878,243.00 , the company said in a SEC Form 4 Filing.
Other Insider transactions have been reported by the company according to SEC Form 4, on Jul 13, 2016, Richard L Harrison (Treasurer, CFO & Secretary) sold 5,700 shares at $30.00 per share price.On Jul 5, 2016, Thomas William Burns (Chief Executive Officer) sold 50,000 shares at $29.12 per share price.Also, On Jun 16, 2016, Chris M. Calcaterra (Chief Commercial Officer) sold 45,464 shares at $28.46 per share price.On Jun 2, 2016, William J Phd Link (director) sold 34,058 shares at $23.98 per share price.
Shares of Glaukos Corp (GKOS) ended Monday, Jul 11, 2016 session in red amid volatile trading. The shares closed down -0.08 points or -0.27% at $29.16 with 1,98,590 shares getting traded. Post opening the session at $29.33, the shares hit an intraday low of $29.15 and an intraday high of $29.52 and the price vacillated in this range throughout the day. The company has a market cap of $948 M and the number of outstanding shares has been calculated to be 3,25,13,368 shares. The 52-week high of Glaukos Corp is $33.92 and the 52-week low is $14.25.
Company has been under the radar of several Street Analysts.Glaukos Corp is Initiated by Cantor Fitzgerald to Buy and the brokerage firm has set the Price Target at $35. The Rating was issued on Jun 3, 2016.
Glaukos Corporation (Glaukos) is an ophthalmic medical technology company. The Company is engaged in the development and commercialization of products and procedures for the treatment of glaucoma. Glaukos has developed the micro-invasive glaucoma surgery (MIGS) for glaucoma treatment. It offers iStent an MIGS device measuring one millimeter long and 0.33 millimeter wide. MIGS procedures involve the insertion of a micro-scale device from within the eye’s anterior chamber through a small corneal incision. Glaukos is also engaged in developing a portfolio of micro-scale injectable therapies including three pipeline products namely the iStent Inject the iStent Supra and iDose. The iStent Inject includes two stents pre-loaded in an auto-injection inserter. The iStent Supra is designed to access an alternative drainage space within the eye. iDose is an implant that is designed to provide a sustained release of a prostaglandin drug to lower intraocular pressure in glaucoma patients.